https://brandessenceresearch.com/ Logo

Antidiabetics Market

Antidiabetics Market Size, Share & Trends Analysis Report

Antidiabetics Market Size, Share, Growth And Forecast By 2028 | Report Analysis 2022-2028

Published
Report ID : BMRC 465
Number of pages : 300
Published Date : Jul 2023
Category : Healthcare
Delivery Timeline : 48 hrs

Antidiabetics Market is valued at USD 67.28 Billion in 2018 and expected to reach USD 132.79 Billion by 2025 with the CAGR of 10.2% over the forecast period.

Market Analysis of Antidiabetics-

Antidiabetics is commonly used to manage diabetes with the help of antidiabetic agent. It helps a person with diabetes, to control their level of glucose (sugar) in the blood. It mainly includes insulin and the oral hypoglycemic agents. There are different classes of anti-diabetic drugs and their selection depends on the nature of the diabetes, age and situation of the person, as well as on some other factors. Antidiabetic agents denote to all the different types of medicine involved in the treatment of diabetes. All these agents aim to reduce blood sugar levels to an acceptable range (called achieving normoglycemia) and relieve symptoms of diabetes such as thirst, excessive urination, and ketoacidosis (a serious complication of diabetes that occurs when the body cannot use glucose as a fuel source).

Global antidiabetics market report is segmented on the basis of product, drug class, route of administration and regional & country level. Based on product global antidiabetics market is classified as rapid acting insulin, long acting insulin, premixed insulin, short acting insulin, and intermediate acting insulin. Based upon drug class, global antidiabetics market is classified into alpha-glucosidase inhibitors, biguanides, sulphonylureas, GLP-1 agonist, meglitinides, DPP-4 inhibitors, sglt-2, and thiazolidinedione. Based upon route of administration, global antidiabetics market is classified as insulin syringe/insulin pen, insulin pump, intravenous infusion, and oral.

The regions covered in this Global Antidiabetics Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of antidiabetics is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players -

Global antidiabetics market report covers prominent players like:

  • AstraZeneca
  • Bayer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Halozyme Inc.
  • Johnson & Johnson
  • Merck
  • Mylan N.V.
  • Novartis
  • Novo Nordisk
  • Oramed Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical
  • Others

Market Dynamics –

Increasing incidence rate of diabetics and rising healthcare expenditure are the fundamental factors which are driving the growth of the market across the globe. As per Diabetes Atlas 8th edition 2017, International Diabetes Federation, there are around 425 million people in the world who are living with diabetes, with Type 2 diabetes accounting for 90 – 95 % of all cases. This number is expected to increase to 629 million people by 2045. However, the high cost of drugs is considered as a major restraint for the market growth within the forecast period. In spite of that, need for development of affordable drugs, especially in emerging nations will result into huge pipeline portfolio of firms, further offering lucrative growth opportunities in the forecast period.

Regional Analysis–

North America is expecetd to dominate the global antidiabetics market due to high market penetration of modern insulin products such as long-acting, rapid acting insulin analogs and DPP-4 drugs such as Januvia, Onglyza and Nesina in this region. In addition, presence of highly advanced healthcare infrastructure, patient awareness levels and reimbursement framework are the others major factors contributing to its large share.

Asia Pacific is expeceted to witness a lucrative growth in this market. This growth is attributed to the rapidly improving healthcare expenditure, growing prevalence of type I and type II diabetes and increasing patient disposable incomes in this region. According to American Diabetes Association, in Asia-Pacific, the incidence of type 1 diabetes for young aged 0-9 years was 6.4 per 100,000 person-years and 7.4 per 100,000 person-years for youth aged 10-19 years. The incidence of type 2 diabetes was 12.1 per 100,000 person-years for youth aged 10–19 years.

Key Benefits for Market Report–

  • Global Antidiabetics Market report covers in depth historical and forecast analysis.
  • Global Antidiabetics Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
  • Global Antidiabetics Market report helps to identify opportunities in market place.
  • Global Antidiabetics Market report covers extensive analysis of emerging trends and competitive landscape.

Market Segmentation:–

By Product

  • Rapid Acting Insulin
  • Long-Acting Insulin
  • Premixed Insulin
  • Short Acting Insulin
  • Intermediate Acting Insulin

By Drug Class

  • Alpha-Glucosidase Inhibitors
  • Biguanides, Sulphonylureas
  • GLP-1 Agonist
  • Meglitinides
  • DPP-4 Inhibitors
  • SGLT-2
  • Thiazolidinedione

By Route of Administration

  • Insulin Syringe/Insulin Pen
  • Insulin Pump
  • Intravenous Infusion
  • Oral

By Regional & Country Analysis:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA
SUMMARY
VishalSawant
Vishal Sawant
Business Development
vishal@brandessenceresearch.com
+91 8830 254 358
Segmentation
Segments

By Product

  • Rapid Acting Insulin
  • Long-Acting Insulin
  • Premixed Insulin
  • Short Acting Insulin
  • Intermediate Acting Insulin

By Drug Class

  • Alpha-Glucosidase Inhibitors
  • Biguanides, Sulphonylureas
  • GLP-1 Agonist
  • Meglitinides
  • DPP-4 Inhibitors
  • SGLT-2
  • Thiazolidinedione

By Route of Administration

  • Insulin Syringe/Insulin Pen
  • Insulin Pump
  • Intravenous Infusion
  • Oral
Country
Regions and Country

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherlands
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of MEA
Company
Key Players
  • AstraZeneca
  • Bayer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Halozyme Inc.
  • Johnson & Johnson
  • Merck
  • Mylan N.V.
  • Novartis
  • Novo Nordisk
  • Oramed Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical
  • Others

+44-1173181773

sales@brandessenceresearch.com

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com

JOIN US

LONDON OFFICE

BrandEssence® Market Research and Consulting Pvt ltd.

124, City Road, London EC1V 2NX

FOLLOW US

Twitter
Facebook
LinkedIn
Skype
YouTube

CONTACT US

1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE

© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®

PaymentModes